Google Parent Plans to Use AI Prowess to Invent Medicines
(Bloomberg) -- Alphabet Inc. said it has created a new company, called Isomorphic Labs, to use artificial intelligence for drug discovery.
The new division was spun out of DeepMind, the London research lab of Google's parent company. DeepMind's algorithms have made huge advances in predicting the shapes of proteins, a technology that could speed up the development of new drugs and upend the pharmaceutical industry.
In a blog post Thursday announcing the move, Demis Hassabis, the co-founder and head of DeepMind, described Isomorphic Labs as “a commercial venture with the mission to reimagine the entire drug discovery process from the ground up with an AI-first approach.”
AI Drug Hunters Could Give Big Pharma a Run for Its Money
Hassabis will be chief executive officer for the new Alphabet company during its “first phase,” a spokesperson said in an email. He will also continue to serve as the head of DeepMind.
Alphabet already has other ventures in medicine. Verily, a biotech unit, has had a wide range of products, but more recently focused on crunching data with partners in the pharmaceutical and health care industry. Calico, a life-extension research firm launched in 2013, has said very little publicly about its work.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.